TAS3681, a novel type of AR antagonist with AR downregulating activity, as a new targeted therapy for aberrant AR-driven prostate cancer.

被引：4
|
作者：
Seki, Masanao [1 ]
Minamiguchi, Kazuhisa [1 ]
Kajiwara, Daisuke [1 ]
Mizutani, Hiroya [1 ]
Yoshida, Shohei [1 ]
Sasaki, Eiji [1 ]
Utsugi, Teruhiro [1 ]
Iwasawa, Yoshikazu [1 ]
机构：
[1] Taiho Pharmaceut Co Ltd, Tsukuba, Ibaraki, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.298
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
298
引用
收藏
页数：1
相关论文
共 15 条
  • [1] TAS3681, a new type of androgen receptor antagonist, disrupts aberrant AR signaling that drives tumor resistance to AR-targeted therapies by downregulating full-length and splice variant AR
    Kajiwara, D.
    Minamiguchi, K.
    Seki, M.
    Mizutani, H.
    Yamamura, K.
    Okajima, S.
    Sasaki, E.
    Utsugi, T.
    Iwasawa, Y.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S127 - S127
  • [2] Effect of a new type androgen receptor antagonist, TAS3681, on ligand-independent AR activation through its AR downregulation activity.
    Kajiwara, Daisuke
    Minamiguchi, Kazuhisa
    Seki, Masanao
    Mizutani, Hiroya
    Aoyagi, Hiroki
    Okajima, Shigeo
    Sasaki, Eiji
    Utsugi, Teruhiro
    Iwasawa, Yoshikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [3] The impact of TAS3681, a new type of androgen receptor antagonist, on aberrant AR signaling that drives tumor resistance to AR-targeted therapies by down-regulating full length and splice variant AR.
    Kajiwara, Daisuke
    Minamiguchi, Kazuhisa
    Seki, Masanao
    Mizutani, Hiroya
    Yamamura, Keisuke
    Okajima, Shigeo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [4] Biological characterization of TAS3681, a new type of androgen receptor antagonist with androgen receptor downregulating activity
    Minamiguchi, K.
    Seki, M.
    Aoyagi, H.
    Mori, T.
    Kajiwara, D.
    Masuko, N.
    Fujita, R.
    Okajima, S.
    Hayashi, Y.
    Sasaki, E.
    Utsugi, T.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 103 - 103
  • [5] TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer
    Yoshida, Shohei
    Kajiwara, Daisuke
    Seki, Masanao
    Tayama, Manabu
    Tanaka, Yuki
    Mizutani, Hiroya
    Fujita, Ryoto
    Yamamura, Keisuke
    Okajima, Shigeo
    Asai, Masanori
    Minamiguchi, Kazuhisa
    MOLECULAR ONCOLOGY, 2024, 18 (08) : 1980 - 2000
  • [6] First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).
    De Bono, Johann S.
    Cook, Natalie
    Yu, Evan Y.
    Lara, Primo
    Wang, Judy S.
    Yamasaki, Yoshihiko
    Yamamiya, Ikuo
    Gao, Ping
    Calleja, Elizabeth Martine
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Antarlides: A New Type of Androgen Receptor (AR) Antagonist that Overcomes Resistance to AR-Targeted Therapy
    Saito, Shun.
    Fujimaki, Takahiro
    Panbangred, Watanalai
    Igarashi, Yasuhiro
    Imoto, Masaya
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (08) : 2728 - 2732
  • [8] The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer.
    Aggarwal, Rahul Raj
    Alumkal, Joshi J.
    Szmulewitz, Russell Zelig
    Higano, Celestia S.
    Bryce, Alan Haruo
    Yu, Margaret K.
    De Boer, Carla
    Choque-Gonzales, Gonzalo
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer
    Li, Xiaoling
    Wang, Yunguan
    Deng, Su
    Zhu, Guanghui
    Wang, Choushi
    Johnson, Nickolas A.
    Zhang, Zeda
    Tirado, Carla Rodriguez
    Xu, Yaru
    Metang, Lauren A.
    Gonzalez, Julisa
    Mukherji, Atreyi
    Ye, Jianfeng
    Yang, Yuqiu
    Peng, Wei
    Tang, Yitao
    Hofstad, Mia
    Xie, Zhiqun
    Yoon, Heewon
    Chen, Liping
    Liu, Xihui
    Chen, Sujun
    Zhu, Hong
    Strand, Douglas
    Liang, Han
    Raj, Ganesh
    He, Housheng Hansen
    Mendell, Joshua T.
    Li, Bo
    Wang, Tao
    Mu, Ping
    CANCER CELL, 2023, 41 (08) : 1427 - +
  • [10] Analysis of AR-driven resistance mechanisms in a phase 1/2 study of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.
    Chi, Kim N.
    Vaishampayan, Ulka N.
    Gordon, Michael S.
    Smith, David C.
    Antonarakis, Emmanuel S.
    Dittamore, Ryan Vance
    Chandhasin, Chan
    Perabo, Frank
    Montgomery, Robert B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12